These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35072888)

  • 21. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings.
    Kornmann O; Mucsi J; Kolosa N; Bandelli L; Sen B; Satlin LC; D'Andrea P
    Respir Med; 2020 Jan; 161():105809. PubMed ID: 32056721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects.
    Vaidya S; Jauernig J; Ethell B; Abdallah N; Machineni S; Drollmann A; Heudi O; Last S; Hahn M; Radhakrishnan R; Ignatenko S; Tillmann HC
    Pulm Pharmacol Ther; 2020 Oct; 64():101964. PubMed ID: 33035700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
    Dahl R; Jadayel D; Alagappan VK; Chen H; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2013; 8():501-8. PubMed ID: 24159259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world characteristics of patients with asthma initiating fluticasone furoate/umeclidinium/vilanterol single-inhaler triple therapy in Japan.
    Oga T; Mita C; Ito R; Requena G; Rothnie KJ; Noorduyn SG; Yuanita L; Yarita M
    Respir Investig; 2024 Jul; 62(4):685-694. PubMed ID: 38796907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada.
    Mtibaa M; Gupta S; Muthukumar M; Marvel J; Kaur H; Ishikawa R; Olivenstein R
    Clinicoecon Outcomes Res; 2021; 13():957-967. PubMed ID: 34887668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Interpretation of Efficacy Outcomes in Pharmacological Studies on Triple Fixed-Dose Combination Therapy for Uncontrolled Asthma: Assessment of IRIDIUM and ARGON Studies.
    Rogliani P; Calzetta L
    J Exp Pharmacol; 2022; 14():1-5. PubMed ID: 35046733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
    Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
    Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.
    Kaplan A; Chapman KR; Anees SM; Mayers I; Rochdi D; Djandji M; Préfontaine D; McIvor A
    Int J Chron Obstruct Pulmon Dis; 2019; 14():249-260. PubMed ID: 30718952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Patalano F; Banerji D
    COPD; 2016 Dec; 13(6):686-692. PubMed ID: 27715335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
    Price D; Keininger D; Costa-Scharplatz M; Mezzi K; Dimova M; Asukai Y; Ställberg B
    Respir Med; 2014 Dec; 108(12):1786-93. PubMed ID: 25307414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways.
    Rogliani P; Ritondo BL; Facciolo F; Matera MG; Nikolaev I; Calzetta L
    Pharmacol Res; 2021 Oct; 172():105801. PubMed ID: 34363950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.
    Rajagopalan K; Bloudek L; Marvel J; Dembek C; Kavati A
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3867-3877. PubMed ID: 30568438
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects
.
    Ren S; Sechaud R; Su Z; Tillmann HC; Hara H; Tan X; Hou J; Woessner R; Zhao R
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):147-155. PubMed ID: 27841152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients.
    Miller D; Vaidya S; Jauernig J; Ethell B; Wagner K; Radhakrishnan R; Tillmann HC
    Respir Res; 2020 Sep; 21(1):248. PubMed ID: 32967685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial.
    Beier J; Watz H; Diamant Z; Hohlfeld JM; Singh D; Pinot P; Jones I; Tillmann HC
    ERJ Open Res; 2021 Apr; 7(2):. PubMed ID: 33898609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Budesonide/Glycopyrronium/Formoterol: A Review in COPD.
    Heo YA
    Drugs; 2021 Aug; 81(12):1411-1422. PubMed ID: 34342835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma.
    Buhl R; Tanase AM; Hosoe M; Cao W; Demin I; Bartels C; Jauernig J; Ziegler D; Patalano F; Hederer B; Kanniess F; Tillmann HC
    Pulm Pharmacol Ther; 2020 Jun; 62():101919. PubMed ID: 32387408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of mometasone/indacaterol/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM study.
    Kostikas K; Maspero JF; Chapman KR; Mezzi K; Jaumont X; Lawrence D; van Zyl-Smit R
    Respir Med; 2023 Oct; 217():107334. PubMed ID: 37392789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis.
    Muro S; Yoshisue H; Kostikas K; Olsson P; Gupta P; Wedzicha JA
    Respirology; 2020 Apr; 25(4):393-400. PubMed ID: 31339215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.